Nasdaq · CIK 0001074871
MODD Modular Medical, Inc.
Insider trading from SEC Form 4. Last filing 12 d ago. Close $2.72 on Oct 9, 2026, +45% from the 52-week low and -86% from the high.
Modular Medical, Inc. (MODD) has 53 SEC Form 4 filings on file from 11 insiders, the latest filed on Oct 1, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
5 open-market trades have been scored at MODD. The newest: Manchester Management Co LLC (Chief Executive Officer) bought $1.3M of stock on Mar 20, 2025, filed Mar 24, 2025, scored 56 (moderate). 2 insiders bought within 14 days of each other around Dec 3, 2024.
MODD closed at $2.72 on Oct 9, 2026, 45% above its 52-week low and 86% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Modular Medical, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 56Moderate | Manchester Management Co LLC Chief Executive Officer buy | $1.3M 677,082 shares | +21% | - | |
| 47Moderate | James E Besser Chief Executive Officer buy | $35k 21,000 shares | +9% | - | |
| 54Moderate | James E Besser Chief Executive Officer buy | $169k 100,000 shares | +69% | - | |
| 49Moderate | Manchester Management Co LLC Chief Executive Officer buy | $250k 166,666 shares | +5% | - | |
| 56Moderate | James E Besser Chief Executive Officer buy | $990k 900,000 shares | +41% | - |
Transactions
The newest 50 of 76 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Steven G Felsher director | AGrant or award Common Stock | +25 | - | - | 8,538 | 12 d ago |
| Sep 30, 2026 | Jeff D Goldberg director | AGrant or award Option to purchase common stockderivative | +250 | - | - | 250 | 12 d ago |
| Sep 30, 2026 | Philip Brent Sheibley director | AGrant or award Option to purchase common stockderivative | +250 | - | - | 250 | 12 d ago |
| Sep 30, 2026 | Morgan C. Frank director, owner | AGrant or award Option to purchase common stockderivative | +62 | - | - | 62 | 12 d ago |
| Sep 30, 2026 | Carmen B Volkart director | AGrant or award Common Stock | +108 | - | - | 1,036 | 12 d ago |
| Sep 30, 2026 | Duane M DeSisto director | AGrant or award Common stock | +83 | - | - | 9,412 | 12 d ago |
| Sep 30, 2026 | Ellen O'Connor Vos director | AGrant or award Option to purchase common stockderivative | +250 | - | - | 250 | 12 d ago |
| Sep 30, 2026 | Morgan C. Frank director, owner | AGrant or award Option to purchase common stockderivative | +250 | - | - | 312 | 12 d ago |
| Sep 30, 2026 | Steven G Felsher director | AGrant or award Option to purchase common stockderivative | +250 | - | - | 250 | 12 d ago |
| May 14, 2026 | Paul DiPerna See Remarks | AGrant or award Option to purchase common stockderivative | +11,218 | $0.00 | $0 | 11,218 | May 18, 2026 |
| Mar 31, 2026 | Morgan C. Frank director, owner | AGrant or award Option to purchase common stockderivative | +62 | - | - | 62 | Apr 9, 2026 |
| Mar 31, 2026 | Morgan C. Frank director, owner | AGrant or award Option to purchase common stockderivative | +250 | - | - | 312 | Apr 9, 2026 |
| Mar 31, 2026 | Jeff D Goldberg director | AGrant or award Option to purchase common stockderivative | +250 | - | - | 250 | Apr 8, 2026 |
| Mar 31, 2026 | Duane M DeSisto director | AGrant or award Common stock | +83 | - | - | 8,544 | Apr 8, 2026 |
| Mar 31, 2026 | Steven G Felsher director | AGrant or award Common Stock | +25 | - | - | 8,473 | Apr 8, 2026 |
| Mar 31, 2026 | Steven G Felsher director | AGrant or award Option to purchase common stockderivative | +250 | - | - | 250 | Apr 8, 2026 |
| Dec 31, 2025 | Duane M DeSisto director | AGrant or award Common stock | +2,500 | - | - | 274,890 | Jan 5, 2026 |
| Dec 31, 2025 | Steven G Felsher director | AGrant or award Common Stock | +750 | - | - | 253,927 | Jan 5, 2026 |
| Dec 31, 2025 | Jeff D Goldberg director | AGrant or award Option to purchase common stockderivative | +7,500 | - | - | 7,500 | Jan 5, 2026 |
| Dec 31, 2025 | Carmen B Volkart director | AGrant or award Common Stock | +3,125 | - | - | 21,460 | Jan 5, 2026 |
| Dec 31, 2025 | Philip Brent Sheibley director | AGrant or award Option to purchase common stockderivative | +7,500 | - | - | 7,500 | Jan 5, 2026 |
| Dec 31, 2025 | Ellen O'Connor Vos director | AGrant or award Option to purchase common stockderivative | +7,500 | - | - | 7,500 | Jan 5, 2026 |
| Dec 31, 2025 | Steven G Felsher director | AGrant or award Option to purchase common stockderivative | +7,500 | - | - | 7,500 | Jan 5, 2026 |
| Dec 31, 2025 | Morgan C. Frank director, owner | AGrant or award Option to purchase common stockderivative | +1,875 | - | - | 1,875 | Jan 2, 2026 |
| Dec 31, 2025 | Morgan C. Frank director, owner | AGrant or award Option to purchase common stockderivative | +7,500 | - | - | 9,375 | Jan 2, 2026 |
| Dec 11, 2025 | Steven G Felsher director | AGrant or award Common Stock | +60,000 | - | - | 253,177 | Dec 15, 2025 |
| Dec 11, 2025 | Philip Brent Sheibley director | AGrant or award Common Stock | +22,000 | - | - | 97,513 | Dec 15, 2025 |
| Dec 11, 2025 | Steven G Felsher director | AGrant or award Warrants to purchase Common Stockderivative | +30,000 | - | - | 30,000 | Dec 15, 2025 |
| Dec 11, 2025 | Philip Brent Sheibley director | AGrant or award Warrants to purchase Common Stockderivative | +11,000 | - | - | 11,000 | Dec 15, 2025 |
| Sep 30, 2025 | Morgan C. Frank director, owner | AGrant or award Option to purchase common stockderivative | +1,875 | - | - | 1,875 | Oct 6, 2025 |
| Sep 30, 2025 | Morgan C. Frank director, owner | AGrant or award Option to purchase common stockderivative | +7,500 | - | - | 9,375 | Oct 6, 2025 |
| Sep 30, 2025 | Jeff D Goldberg director | AGrant or award Option to purchase common stockderivative | +7,500 | - | - | 7,500 | Oct 3, 2025 |
| Sep 30, 2025 | Carmen B Volkart director | AGrant or award Common Stock | +3,125 | - | - | 18,335 | Oct 2, 2025 |
| Sep 30, 2025 | Philip Brent Sheibley director | AGrant or award Option to purchase common stockderivative | +7,500 | - | - | 7,500 | Oct 2, 2025 |
| Sep 30, 2025 | Ellen O'Connor Vos director | AGrant or award Option to purchase common stockderivative | +7,500 | - | - | 7,500 | Oct 2, 2025 |
| Sep 30, 2025 | Duane M DeSisto director | AGrant or award Common stock | +2,500 | - | - | 272,390 | Oct 2, 2025 |
| Sep 30, 2025 | Steven G Felsher director | AGrant or award Common Stock | +750 | - | - | 193,177 | Oct 2, 2025 |
| Sep 30, 2025 | Steven G Felsher director | AGrant or award Option to purchase common stockderivative | +7,500 | - | - | 7,500 | Oct 2, 2025 |
| Jun 30, 2025 | Duane M DeSisto director | AGrant or award Common stock | +2,500 | - | - | 269,890 | Jul 2, 2025 |
| Jun 30, 2025 | Steven G Felsher director | AGrant or award Common Stock | +750 | - | - | 192,427 | Jul 2, 2025 |
| Jun 30, 2025 | Morgan C. Frank director, owner | AGrant or award Option to purchase common stockderivative | +1,875 | - | - | 1,875 | Jul 2, 2025 |
| Jun 30, 2025 | Jeff D Goldberg director | AGrant or award Option to purchase common stockderivative | +3,297 | - | - | 3,297 | Jul 2, 2025 |
| Jun 30, 2025 | Philip Brent Sheibley director | AGrant or award Option to purchase common stockderivative | +7,500 | - | - | 7,500 | Jul 2, 2025 |
| Jun 30, 2025 | Carmen B Volkart director | AGrant or award Common Stock | +3,125 | - | - | 15,210 | Jul 2, 2025 |
| Jun 30, 2025 | Ellen O'Connor Vos director | AGrant or award Option to purchase common stockderivative | +7,500 | - | - | 7,500 | Jul 2, 2025 |
| Jun 30, 2025 | Steven G Felsher director | AGrant or award Option to purchase common stockderivative | +7,500 | - | - | 7,500 | Jul 2, 2025 |
| Jun 30, 2025 | Morgan C. Frank director, owner | AGrant or award Option to purchase common stockderivative | +7,500 | - | - | 9,375 | Jul 2, 2025 |
| Apr 24, 2025 | Kevin Schmid Chief Operating Officer | AGrant or award Option to purchase common stockderivative | +50,000 | $0.00 | $0 | 50,000 | Apr 28, 2025 |
| Apr 24, 2025 | Manchester Management Co LLC Chief Executive Officer | AGrant or award Option to purchase common stockderivative | +125,000 | $0.94 | $118k | 125,000 | Apr 28, 2025 |
| Apr 24, 2025 | Paul DiPerna See Remarks | AGrant or award Option to purchase common stockderivative | +200,000 | $0.00 | $0 | 200,000 | Apr 28, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- James E BesserChief Executive Officer
- Duane M DeSistodirector
- Paul DiPernaSee Remarks
- Steven G Felsherdirector
- Morgan C. Frankowner, other, director, ceo, officer
- Jeff D Goldbergdirector
- Manchester Management Co LLCChief Executive Officer
- Kevin SchmidChief Operating Officer
- Philip Brent Sheibleydirector
- Carmen B Volkartdirector
- Ellen O'Connor Vosdirector
Questions about MODD
Answered from the filings on this page, as of the latest one.
Are insiders buying MODD?
No. In the last 90 days no insider at Modular Medical, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade MODD on the open market?
Manchester Management Co LLC (Chief Executive Officer) bought $1.3M of MODD on Mar 20, 2025 and filed the Form 4 on Mar 24, 2025. InsiderTell scored 56 (moderate).
How many insiders file Form 4 at Modular Medical, Inc.?
11 people have filed a Form 4 at Modular Medical, Inc., among them James E Besser (Chief Executive Officer), Duane M DeSisto (director), Paul DiPerna (See Remarks). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.